临床试验/JPRN-UMIN000011911

JPRN-UMIN000011911已完成未知

Observation study for Japanese patients with head and neck cancer by combination therapy with cetuximab - Observation study for Japanese patients with head and neck cancer by combination therapy with cetuximab

Japanese Oncology Radiation Study Group0 个研究点目标入组 300 人开始时间: 2013年10月1日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: Japanese Oncology Radiation Study Group
入组人数: 300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1)Previous history of cetuximab treatment before 31th Dec 2012 2)Severe allergic reaction (G3-4) of any component in Erbitax 3) Critical comorbidity otherwise head and neck cancer 4) Second primary cancer except when there has been no evidence of the disease for more than 3 years without any treatment. (Exclude of carcinoma in situ or mucosal cancer which is estimated as stable by local treatment) 5)Positive HbsAg without adequate anti-viral treatment 6) Pregnancy or lactation 7)Any inappropriate reason for registration by physicians

研究者

发起方

Japanese Oncology Radiation Study Group

相似试验

Multicenter registry study of Japanese patients with inflammatory bowel disease with COVID-19inflammatory bowel disease COVID-19

JPRN-UMIN000040656Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine200

Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.

JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33

A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of AZD2171 Alone and in Combination With AZD2171 and Pac/CarbCarcinoma, Non-Small-Cell Lung

JPRN-jRCT2080220478AstraZeneca

进行中（未招募）

An extension study for seven patients in Japan with neuromyelitis optica spectrum disorder who completed the open-label period of study CD-IA-MEDI-551-1155 of Inebilizumab

JPRN-jRCT2051210017Sato Toshiyuki7

Epidemiological study on Japanese patient with multiple sclerosisClinically isolated syndrome (CIS), Radiologically isolated syndrome (RIS), multiple sclerosis (MS)

JPRN-UMIN000038060Kyushu University1,000